Clearside launches phase 2 clinical trial for triamcinolone acetonide

Clearside Biomedical has begun enrollment for a phase 2 clinical trial to evaluate triamcinolone acetonide in the treatment of macular edema associated with retinal vein occlusion, according to a press release.Clearside’s proprietary formulation of triamcinolone acetonide, CLS-TA, is administered via suprachoroidal injection with the company’s micro-injector.

IOP outcomes may not be affected by postop steroids after combined cataract, trabecular micro-bypass surgery

CORONADO, Calif. — The use of steroids after trabecular micro-bypass stent surgery and concomitant cataract surgery may not cause negative IOP and medication use outcomes, according to a presentation here.In a poster presented at the American Glaucoma Society meeting, Aaron Winter, MD, and colleagues compared the outcomes of open-angle glaucoma patients who received a trabecular micro-bypass stent and underwent cataract surgery. Postoperatively, 52 patients received topical antibiotics and NSAIDs for 1 week and 4 weeks and 52 patients received topical steroids for 4 weeks.

Fixed dose combination proves superior in reducing diurnal IOP

CORONADO, Calif. — A fixed-dose combination of IOP-lowering medications reduced diurnal IOP more effectively than its constituent components dosed individually, according to a scientific poster presented here.Jason Bacharach, MD, and colleagues reported that PG324 ophthalmic solution (Aerie Pharmaceuticals) proved superior to both latanoprost and AR-13324 (Aerie) in reducing IOP over 1 month.